Search Results
Dec 03, 2025, 08:30 ET Foresight Diagnostics Announces Multiple Presentations in Lymphoma Featuring PhasED-Seq™ Ultrasensitive MRD Analysis at the upcoming ASH Annual Meeting
This year's presentations reflect the growing integration of highly sensitive, circulating tumor DNA (ctDNA)-based MRD testing into clinical studies across hematologic malignancies. Academic groups and pharmaceutical partners are increasingly deploying
More news about: Foresight Diagnostics, Inc.
Dec 03, 2025, 08:00 ET STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy
MV platform and expertise in bone marrow-targeted in vivo delivery. As the Prime Awardee, STRM will collaborate with Ginkgo Bioworks (NYSE: DNA), the University of British Columbia (UBC), and Advanced Bioprocess Services (ABS) to develop in vivo CAR-T therapeutics. The partnership will
More news about: STRM.BIO
Dec 03, 2025, 07:30 ET ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death.The U.S. Food and Drug
More news about: ADC Therapeutics SA
Dec 03, 2025, 05:00 ET MEXC Appoints Vugar Usi as Chief Operating Officer to Accelerate Global Growth and Redefine User-First Crypto Trading Experience
innovation, rapid expansion, and sustained momentum across international markets. What truly sets the company apart for me is its deep, mission-driven DNA. As the new Chief Operating Officer, my focus is not on incremental change, but on fundamentally raising the standard for what a global, retail-first
More news about: MEXC
Dec 03, 2025, 05:00 ET MEXC Appoints Vugar Usi as Chief Operating Officer to Accelerate Global Growth and Redefine User-First Crypto Trading Experience
innovation, rapid expansion, and sustained momentum across international markets. What truly sets the company apart for me is its deep, mission-driven DNA. As the new Chief Operating Officer, my focus is not on incremental change, but on fundamentally raising the standard for what a global, retail-first
More news about: MEXC
Dec 02, 2025, 12:04 ET DNA&STONE NAMES JESS WATTS FIRST-EVER CHIEF STRATEGY OFFICER
more about DNA&STONE, please visit www.dnaandstone.com.About DNA&STONEDNA&STONE
More news about: DNA&STONE
Dec 02, 2025, 09:30 ET Embark Showcases Pet Wellness Leadership at Pet Connect USA with Vision for Connected, Personalized Care
expanded vision for the future of pet wellness at Pet Connect USA, where Chief Executive Amish Desai will present the company's evolution from a leading DNA test provider to a connected pet care platform built on science, personalization and adaptive support.
More news about: Embark Veterinary, Inc.
Dec 02, 2025, 09:00 ET Melanoma Research Alliance Launches Melanoma Biorepository to Accelerate Research and Improve Patient Outcomes
surgeries, regardless of where they receive care. These specimens may be used for immediate research, stored for future studies or further processed into DNA, RNA or protein for advanced analysis. They may also support the creation of vital scientific resources such as cell lines, tissue microarrays, and patient-derived
More news about: Melanoma Research Alliance
Dec 02, 2025, 08:49 ET Tiger Infrastructure Partners Completes Transformational Growth Capital Investment in Raptor Waste Solutions, an Integrated Waste Logistics Platform in the Greater Kansas City Area
Infrastructure Founder, CEO & CIO, stated, "Shawn and Kit's vision to bring innovative solutions to a critical infrastructure industry aligns with our DNA as a first mover in growth infrastructure. We have been impressed by Raptor and the success they've had in delivering best-in-class services, reducing
More news about: Tiger Infrastructure Partners
Dec 02, 2025, 08:39 ET Tiger Infrastructure Partners Completes Transformational Growth Capital Investment in Raptor Waste Solutions, an Integrated Waste Logistics Platform in the Greater Kansas City Area
"Raptor's vision to bring innovative solutions to a critical infrastructure industry aligns with our DNA as a first mover in growth infrastructure" - Emil W. Henry, Jr.Shawn and Kit created Raptor to provide a more modern and efficient solution
More news about: Tiger Infrastructure Partners
Dec 02, 2025, 08:30 ET MDA SPACE NAMED TO INC.'S 2025 BEST IN BUSINESS LIST IN INNOVATION
vision into an achievable mission – bringing to bear a one-of-a-kind mix of experience, engineering excellence and wide-eyed wonder that's been in our DNA since day one. For those who dream big and push boundaries on the ground and in the stars to change the world for the better, we'll take you there. For
More news about: MDA Space
Dec 02, 2025, 08:00 ET Atlas Data Storage Introduces the World's First Scalable DNA Data Storage Offering
Dec. 2, 2025 /PRNewswire/ -- Atlas Data Storage, the leader in synthetic DNA data storage, today announced Atlas Eon 100, the first scalable DNA data storage service. DNA is the only storage medium that preserves data permanently in nature's most enduring format.
More news about: Atlas Data Storage
Dec 02, 2025, 07:24 ET Kimi Räikkönen joins Nokian Tyres' team as Brand Ambassador
amplify its international recognition."Some collaborations just make sense, and this is one of them. Kimi Räikkönen and Nokian Tyres share the same DNA: Finnish roots, uncompromising performance, and the ability to thrive under pressure. Both are built for extremes - whether it's conquering the racetrack
More news about: Nokian Tyres
Dec 01, 2025, 16:06 ET Genetic Research Pinpoints a Lethal Risk Linked to Adams-Oliver Syndrome
AOS."AOS-associated RBPJ variants do not function as loss-of-function alleles but instead act as dominant-negative proteins that sequester cofactors from DNA," the study states.Can NOTCH1 signals be boosted? "Prior studies have supported the idea that dysregulated NOTCH1 signaling
More news about: Cincinnati Children's Hospital Medical Center
Dec 01, 2025, 11:08 ET Balega® to Showcase New Products & Host Demo Runs at The Running Event 2025
the Industry Awards Dinner on Thursday night, recognizing the account that best exemplifies the community-driven approach that is core to the brand's DNA.Additional OpportunitiesAs an extension of the TRE Weekend, Balega is partnering with Fleet Feet San Antonio to have a 10x20 booth
More news about: Implus LLC
Dec 01, 2025, 09:00 ET Youth Switch Longevity Supplement Features Clinically Studied Ingredients for Aging Markers
shorten with each cell division, functioning as biological aging clocks that determine cellular lifespan and overall vitality. When these protective DNA caps become too short, cells stop functioning properly, leading to age-related decline. PureHealth Research's
More news about: PureHealth Research
Dec 01, 2025, 09:00 ET 100,000 Participants and Counting: Massive Global Genetic Dataset Powers Discoveries in Parkinson's Disease
2025 /PRNewswire/ -- Researchers have reached a major milestone in the effort to understand and treat Parkinson's disease: more than 100,000 DNA samples from study participants around the world have now been genotyped and sequenced through the Global Parkinson's Genetics Program (GP2), a resource
More news about: Aligning Science Across Parkinson's
Dec 01, 2025, 09:00 ET Biocodex To Present New Data at the American Epilepsy Society (AES) 2025 Annual Meeting
chain.The Biocodex global organization comprises 1,700 employees who share common values, embodied in their daily missions and rooted in the company's DNA.To learn more about Biocodex visit:
More news about: Biocodex, Inc.
Dec 01, 2025, 08:45 ET Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium
patients have at least one PSMA-negative tumor lesion. Ac-225 delivers high-linear-energy-transfer alpha particles that induce irreparable double-strand DNA breaks, offering superior potency over beta emitters like Lutetium-177 (177Lu), and has a shorter tissue path length that may reduce off-target toxicity.
More news about: Actinium Pharmaceuticals, Inc.
Dec 01, 2025, 08:00 ET Consumer Edge Releases 2026 Restaurant Outlook: Value Dining Outperforms Hype as Chili's, Texas Roadhouse and Raising Cane's Show Momentum
consumers have adapted to years of inflationary pressures, and the brands seeing real momentum in this industry are those that treat value as part of their DNA, rather than a short-term promotion."Consumer Edge tracks more than 600 restaurant brands across all major categories, including casual dining,
More news about: Consumer Edge
Dec 01, 2025, 06:00 ET IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
payload provides a strong mechanistic rationale for combining IDE034 with IDEAYA's PARG inhibitor, IDE161. TOP1 inhibition induces replication stress and DNA damage, which can increase reliance on the PARG pathway; therefore, a IDE034 and IDE161 combination approach may enhance anti-tumor activity in patients
More news about: IDEAYA Biosciences, Inc.
Nov 28, 2025, 00:13 ET The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment.
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 27, 2025, 17:31 ET Rhabdomyosarcoma Market is Expected to Rise Throughout Forecast Period (2025-2034) with Promising Drug Candidates in Pipeline | DelveInsight
in recurrent pediatric cancers at the AACR 2024 conference.ONIVYDE is a cancer therapy that inhibits the TOP1 enzyme, which is essential for DNA replication and cell division. By blocking this enzyme, the drug prevents cancer cell proliferation, leading to cell death. In ONIVYDE, irinotecan is
More news about: DelveInsight Business Research LLP
Nov 27, 2025, 10:30 ET Pet DNA Testing Market to Reach $960.7 Million, Globally, by 2034 at 9.3% CAGR: Allied Market Research
the Report on Global Pet DNA Testing Market 2034 - https://www.alliedmarketresearch.com/request-sample/A325828Market IntroductionThe pet DNA testing market encompasses
More news about: Allied Market Research
Nov 26, 2025, 09:35 ET Exposing the Deadly Guesswork in Cancer Care: JOTO PR Signs First Ascent Biomedical
First Ascent Biomedical is revolutionizing cancer treatment with its AI-driven drug prediction platform. By integrating functional drug validation, DNA/RNA sequencing, and AI, the company identifies personalized therapies for all solid and liquid tumors, delivering actionable treatment plans to physicians
More news about: JOTO PR